STOCK TITAN

Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Aytu BioPharma (Nasdaq: AYTU) entered into a definitive merger agreement for Rosemont Pharmaceuticals Holdings to acquire it for $2.70 per share. The all-cash transaction will begin with a tender offer by a Rosemont subsidiary, followed by a merger buying remaining shares at the same price, except shares with properly exercised appraisal rights.

Aytu's board unanimously approved the agreement, and closing is anticipated in late December 2026. Completion requires tender of at least a majority of outstanding common shares and exercise or termination of certain warrants. Rosemont intends to begin the offer and file Schedule TO within 10 business days; Aytu will file Schedule 14D-9 substantially concurrently. Executive officers, directors and certain stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management signed agreements to tender their shares and exercise or terminate their warrants before the effective time.

Loading...
Loading translation...
3 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Rosemont's definitive acquisition agreement provides Aytu shareholders $2.70 per share in cash.
  • Minor pointAytu's board unanimously approved the acquisition agreement.
  • Minor pointExecutive officers, directors and certain Nantahala- and Stonepine-affiliated stockholders signed tender and support agreements.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Completion requires tender of at least a majority of Aytu's outstanding common shares.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Completion also depends on exercise or termination of certain outstanding warrants.

Key Figures

Tender offer price: $2.70 per share Minimum tender condition: At least a majority of outstanding shares Tender offer commencement: Within 10 business days +1 more
Tender offer price
$2.70 per share
Proposed all-cash tender offer; same price for shares acquired in the second-step merger
Minimum tender condition
At least a majority of outstanding shares
Condition to the tender offer and merger
Tender offer commencement
Within 10 business days
Rosemont intends to commence the offer and file a Schedule TO
Anticipated closing
Late December 2026
Subject to satisfaction or waiver of tender offer conditions

Key Terms

tender offer, schedule to, schedule 14d-9, appraisal rights
4 terms
tender offer financial
"through a tender offer for $2.70 per share."
A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.
View in glossary
schedule to regulatory
"file a Schedule TO within 10 business days"
A phrase indicating that a company plans or intends to hold an event, publish information, or take an action at a specified future time, but that the timing is not guaranteed and may change. For investors it signals an expected milestone—like an earnings call, product launch, or filing—so think of it as a calendar note rather than a firm promise; timing shifts can affect trading, expectations, and planning.
View in glossary
schedule 14d-9 regulatory
"Aytu will file a Schedule 14D-9 with respect to the tender offer"
Schedule 14D-9 is a filing with the U.S. Securities and Exchange Commission in which a company publicly states its response and recommendation to an outside bid to buy its shares (a tender offer). Think of it as the company’s advisory note to shareholders explaining whether to sell, keep, or seek alternatives, and why, with facts and reasoning. Investors rely on it to gauge management’s view of the offer’s fairness and the likely impact on value and strategy.
appraisal rights regulatory
"other than shares for which appraisal rights are properly exercised"
A legal right that lets shareholders who dislike the price or terms of a buyout, merger or other major corporate change ask for an independent determination of the fair value of their shares instead of accepting the deal price. Think of it like asking a neutral referee to set the payout if you believe the offered price is too low. For investors, appraisal rights can provide a way to recover a higher cash value but can be slow, costly and create uncertainty around deal outcomes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

DENVER, CO / ACCESS Newswire / November 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it has entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc. ("Rosemont"), pursuant to which Rosemont would acquire Aytu, through a tender offer for $2.70 per share.

Under the terms of the merger agreement, a wholly-owned subsidiary of Rosemont will commence a tender offer to acquire all outstanding shares of Aytu common stock. The transaction is structured as a tender offer to be followed by a merger, subject to customary conditions to the tender offer and merger, including the tender of shares representing at least a majority of the total number of outstanding shares of Aytu common stock and the exercise or termination of certain outstanding warrants. Following the successful completion of the tender offer, Rosemont will acquire all remaining shares not tendered in the tender offer (other than shares for which appraisal rights are properly exercised) through a second-step merger at the same price paid in the tender offer.

Rosemont intends to commence the tender offer and file a Schedule TO within 10 business days, and Aytu will file a Schedule 14D-9 with respect to the tender offer substantially concurrently with the commencement of the tender offer, each of which will include additional details on the transaction and process undertaken by the Company.

The transaction was unanimously approved by the Aytu board of directors and closing is anticipated to occur in late December 2026, subject to the satisfaction or waiver of the conditions to the tender offer. Aytu's executive officers, directors and certain stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management, have signed tender and support agreements under which such stockholders agreed, among other things, to tender their shares in the tender offer and to the termination or exercise of any warrants held by them prior to the Effective Time, in exchange for the consideration payable in connection with the transaction in accordance with the terms of such warrants.

Josh Disbrow, Chief Executive Officer of Aytu BioPharma, said: "This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve. We see a strong strategic fit between our portfolio and Rosemont's experience developing and commercializing specialty medicines. Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need."

Alok Sonig, Chief Executive Officer of Rosemont Pharmaceuticals, said: "The proposed acquisition of Aytu marks an important step in Rosemont's US growth strategy. Aytu has built an established CNS adult and pediatric-focused specialty pharmaceutical business with talented people, a differentiated portfolio and proven commercial capabilities. Together with Rosemont's product development, regulatory, manufacturing and commercial expertise, we believe we can build a strong platform for future growth. We look forward to welcoming the Aytu team once the transaction is complete."

Canaccord Genuity is acting as financial advisor to Aytu BioPharma. Dorsey & Whitney LLP is serving as legal counsel to Aytu in connection with the transaction. Bourne Partners is acting as financial advisor to Rosemont. Ropes & Gray LLP is serving as legal counsel to Rosemont.

About Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. Aytu's prescription products include EXXUA® (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention-deficit/hyperactivity disorder (ADHD). Aytu is committed to delivering its medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.

About Rosemont Pharmaceuticals

Rosemont Pharmaceuticals is a global pharmaceutical company specialising in the development, manufacture and supply of oral liquid medicines. For nearly 60 years, Rosemont has focused on creating alternative dosage forms that help address the needs of patients who may have difficulty swallowing solid oral medicines.

Through its broad portfolio across multiple therapeutic areas, Rosemont works to support patients, caregivers and healthcare professionals by improving access to medicines in formulations designed to meet diverse patient needs. Rosemont Pharmaceuticals is headquartered in Leeds in the United Kingdom and serves patients across international markets through a growing portfolio of licensed medicines.

For more information, please visit: www.rosemontpharma.com

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: uncertainties as to the timing of the tender offer and the merger; uncertainties as to how many Aytu stockholders will tender their shares in the tender offer; the possibility that the conditions to the tender offer and the merger may not be satisfied or waived; the occurrence of any event that could give rise to the termination of the merger agreement; the effects of the transaction on relationships with employees, customers, suppliers and other business partners; potential stockholder litigation or regulatory action relating to the transaction; the Company's overall financial and operational performance, potential adverse changes to the Company's financial position or its business, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of its products, its partners performing their required activities, its anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaborations. The Company also refers you to the risks described in "Risk Factors" in Part I, Item 1A of the Company's most recent Annual Report on Form 10-K and in the other reports and documents it files with the United States Securities and Exchange Commission, as well as the tender offer documents to be filed by Rosemont and the Schedule 14D-9 to be filed by the Company.

Additional Information and Where to Find It

The tender offer for all of the outstanding shares of Aytu described in this communication has not yet commenced. This press release is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Rosemont and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. A solicitation and offer to buy outstanding shares of Aytu will only be made pursuant to the tender offer materials that Rosemont and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Rosemont and its acquisition subsidiary will file tender offer materials on Schedule TO, and Aytu will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF AYTU ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF AYTU SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of Aytu at no expense to them on the SEC's website at www.sec.gov and (once they become available) will be mailed to the stockholders of Aytu free of charge. Additional copies may be obtained for free by contacting Aytu, or by contacting Sodali & Co, the information agent for the Offer, toll-free at (800) 662-5200 or at AYTU.info@investor.sodali.com. The information contained in, or that can be accessed through, the SEC's website is not a part of, or incorporated by reference herein. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Aytu files annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Aytu with the SEC for free on the SEC's website at www.sec.gov.

Contacts for Aytu

Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com

Robert Blum
Lytham Partners
aytu@lythampartners.com

SOURCE: Aytu BioPharma, Inc.



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much will Rosemont pay Aytu BioPharma shareholders in the acquisition?

Rosemont will pay $2.70 per share in cash under the merger agreement. Following successful completion of the tender offer, remaining shares will be acquired at the same price through a second-step merger, except shares for which appraisal rights are properly exercised.

When is the Rosemont acquisition of Aytu BioPharma expected to close?

Closing is anticipated in late December 2026, subject to satisfaction or waiver of the tender-offer conditions. Rosemont intends to commence the tender offer within 10 business days.

Keep reading